Key result
A fixed-dose combination of perindopril and indapamide resulted in a higher mean efficacy-tolerability score compared to sequential monotherapy and stepped-care in hypertensive patients.
Why the study?
Does a fixed-dose combination of perindopril/indapamide improve a combined efficacy and tolerability score compared to sequential monotherapy or stepped-care in patients with hypertension?
RCT (n=329)
Double-blind
random allocation
Yes
Does a fixed-dose combination of perindopril/indapamide improve a combined efficacy and tolerability score compared to sequential monotherapy or stepped-care in patients with hypertension?
A novel scoring system integrating efficacy and tolerability demonstrated that a fixed-dose combination of perindopril and indapamide yielded better overall outcomes than sequential monotherapy or stepped-care in hypertension management.
Answers are grounded in this paper and cite their sources.
Supports upfront fixed-dose perindopril/indapamide in hypertension; extends evidence for combinations over sequential strategies.
A score system integrating the evolution of efficacy and tolerability over time was applied to a subpopulation of the STRATHE trial, a trial performed according to a parallel group design, with a double-blind, random allocation to either a fixed-dose combination strategy (perindopril/indapamide 2 mg/0.625 mg, with the possibility to increase the dose to 3 mg/0.935 mg, and 4 mg/1.250 mg if needed, n = 118), a sequential monotherapy approach (atenolol 50 mg, followed by losartan 50 mg and amlodipine 5 mg if needed, n = 108), or a stepped-care strategy (valsartan 40 mg, followed by valsartan 80 mg and valsartan 80 mg+ hydrochlorothiazide 12.5 mg if needed, n = 103). The aim was to lower blood pressure below 140/90 mmHg within a 9-month period. The treatment could be adjusted after 3 and 6 months. Only patients in whom the study protocol was strictly applied were included in this analysis. At completion of the trial the total score averaged 13.1 +/- 70.5 (mean +/- SD) using the fixed-dose combination strategy, compared with -7.2 +/- 81.0 using the sequential monotherapy approach and -17.5 +/- 76.4 using the stepped-care strategy. In conclusion, the use of a score system allows the comparison of antihypertensive therapeutic strategies, taking into account at the same time efficacy and tolerability. In the STRATHE trial the best results were observed with the fixed-dose combination containing low doses of an angiotensin enzyme converting inhibitor (perindopril) and a diuretic (indapamide).
No takes yet. Share an insight, caveat, or question.
Bernard Waeber (2008) conducted an RCT in Hypertension (n=329). Fixed-dose combination strategy (perindopril/indapamide) vs. Sequential monotherapy (atenolol, losartan, amlodipine) or stepped-care strategy (valsartan, hydrochlorothiazide) was evaluated on Total score integrating efficacy and tolerability over 9 months. A fixed-dose combination of perindopril and indapamide resulted in a higher mean efficacy-tolerability score compared to sequential monotherapy and stepped-care in hypertensive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: